Rhumbline Advisers Increases Position in Galapagos NV (NASDAQ:GLPG)

Rhumbline Advisers lifted its position in shares of Galapagos NV (NASDAQ:GLPG) by 21.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 4,578 shares of the biotechnology company’s stock after purchasing an additional 814 shares during the period. Rhumbline Advisers’ holdings in Galapagos were worth $113,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GLPG. Wellington Management Group LLP boosted its stake in Galapagos by 3.9% in the fourth quarter. Wellington Management Group LLP now owns 495,217 shares of the biotechnology company’s stock valued at $20,131,000 after acquiring an additional 18,552 shares in the last quarter. Greenlight Capital Inc. increased its stake in Galapagos by 4.0% in the fourth quarter. Greenlight Capital Inc. now owns 162,578 shares of the biotechnology company’s stock valued at $6,609,000 after purchasing an additional 6,200 shares during the period. Vestal Point Capital LP purchased a new stake in shares of Galapagos in the fourth quarter valued at about $5,284,000. AlphaCentric Advisors LLC boosted its stake in shares of Galapagos by 3.3% during the second quarter. AlphaCentric Advisors LLC now owns 108,500 shares of the biotechnology company’s stock worth $2,689,000 after buying an additional 3,500 shares during the period. Finally, Monaco Asset Management SAM grew its holdings in shares of Galapagos by 148.3% during the first quarter. Monaco Asset Management SAM now owns 16,744 shares of the biotechnology company’s stock worth $539,000 after buying an additional 10,000 shares during the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GLPG shares. Leerink Partners started coverage on Galapagos in a research report on Monday, September 9th. They set a “market perform” rating and a $24.00 price objective for the company. Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a research note on Monday, September 9th. Finally, Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. According to data from MarketBeat, Galapagos has an average rating of “Hold” and an average price target of $31.00.

Galapagos Stock Down 1.7 %

Galapagos stock opened at $28.79 on Tuesday. The firm’s 50-day moving average is $27.58 and its two-hundred day moving average is $28.18. Galapagos NV has a 12-month low of $24.16 and a 12-month high of $42.46.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.